Leaving the flaming hulk of the Trump administration aside for a moment, I thought this piece from Reuters to be of interest. Unexpected, but welcome.
tl;dr - big pharma is not all that interested in a massive rollback of FDA regulation.
The primary reason seems to be that drugs that actually make it through the regulatory hoops have demonstrated value and safety, and thus can command a premium price. But patient safety also pops up on the radar, which is... a good thing. Nobody wants people to be harmed by pharmaceuticals released to market with insufficient vetting - glad to hear it!
In any case, worth a read IMO.